MD Revenue Group provides specialized, high-performance revenue cycle management for independent hematology and oncology practices, multi-physician oncology groups, and specialized infusion centers. We eliminate "Capital Erosion" by mastering the complex 2026 shifts in high-cost biologic authorizations, J-code unit-level precision, and the mandatory waste reporting (JZ/JW) requirements that now define oncological margin protection. Our Medical Billing Services are engineered to transform your oncology practice from a high-liability drug purchaser into a proactive capital recovery engine.
For an independent hematologist-oncologist, the choice to outsource RCM isn't about giving up control, it's about gaining technical leverage against aggressive payers who want to default your medication reimbursement to "Invoice Cost." Our Medical Billing & RCM Services provide the administrative backbone required to allow your oncologists to focus on patient outcomes rather than financial liability.
As you add new infusion protocols, specialized molecular diagnostics, or specialized radiation oncology equipment, your billing scales instantly without the need for additional Credentialing staff or office space.
By catching technical and mathematical errors (like Payer Enrollment gaps or unlinked pharmacy contracts) *before* submission, we dramatically accelerate your cash flow for clinical growth.
We build "Audit-Armor" into the foundation of your oncology practice. Our experts ensure that every infusion log, every drug waste record, and every molecular authorization is "Ready for Scrutiny" before it ever leaves your office.
Oncology is a specialty defined by extreme financial risk and the administrative burden of managing medications that can cost upwards of $20,000 per dose. In 2026, the cost of cancer care medications and the administrative friction of authorization have reached a point where a single "Unit-Level" or "Modifier" error can cause a practice to lose its entire procedural margin.
A primary source of revenue erosion for oncology practices is the failure to perfectly synchronize the drug units administered with the units allowed by the payer’s specific medical policy. In 2026, if the HCPCS units don't match the "Volume-to-Dose" calculation in the clinical chart, the claim is auto-denied or downcoded. We implement Revenue Integrity protocols to ensure every milligram of high-cost chemotherapy is captured.
For 2026, CMS and major commercial payers have made drug waste reporting (Modifier -JW for discarded amounts, Modifier -JZ for zero waste) mandatory for all single-dose vial medications. Most oncology groups lose 8-10% of their drug revenue simply by failing to document and bill the "Discarded Units" correctly. MDRG’s Revenue Cycle Management experts specialize in technical waste reconciliation to avoid these systemic losses.
Payers are increasingly denying biomarker and genetic testing claims (81200–81599) due to "Lack of Specificity" in the treatment plan. In 2026, payers require the testing to be explicitly linked to a "Next-Line Therapy" decision. Our team manages the "Authorization Path" to ensure these high-cost diagnostics are paid on the first pass.
Topical authority in oncology RCM involves mastering the 96400-series CPT codes and the nuances of high-complexity drug delivery systems. Our oncology-certified coders ensure every Billing & Revenue Cycle Management (RCM) submission is optimized for technical success.
Push vs. Infusion vs. Extended time
Exact HCPCS units & waste capture
Bundling & technical component split
Managing the 60-min clinical threshold
2026 mandatory waste reporting
2026 mandatory zero-waste reporting
Defending evaluation parity
In 2026, oncology billing is a battle of "Clinical Calculation." Payers are no longer just looking for coding errors; they are using AI-driven auditing to challenge the *dosage* and *waste* of high-cost biologics. We defend your revenue against these three high-frequency rejection types:
Payer bots often deny entire medication claims if they detect a "Vial Mismatch", where a single-use vial was billed but no waste (-JW) or zero-waste (-JZ) modifier was applied. In 2026, this is the #1 reason for oncology payment delay.
Many payers have updated their 2026 audit triggers for genetic testing. If the chart doesn't explicitly state how the test result will change the chemotherapy protocol, the testing is denied as "Investigational."
For newer specialized immunotherapy mappings or CAR-T cell transitions, payers often trigger "Experimental" denials even for FDA-cleared protocols.
In 2026, the key to oncology revenue is the "Technical Intensity Narrative." We help your providers implement "Audit-Armor" charting strategies that signal authority to payer algorithms. This includes using "Trigger Phrases" for testing necessity and automating the capture of specialized infusion technical data.
We help you structure your infusion records so that the "Technical Necessity" of a separately identifiable encounter is undeniable to even the most aggressive automated payer bots.
We teach your team how to describe patient presentation in a way that reflects the true "Diagnostic Intensity" of the work, reducing the risk of automated downcoding.
MDRG acts as your practice’s "Oncology RCM Command Center." We focus entirely on Revenue Cycle Management efficiency so you can focus on clinical stabilize and patient care.
We synchronize with your EHR (OncoEMR, Aria, Mosaiq, etc.) to establish a clean, high-speed data bridge.
Every oncology claim is scrubbed for 2026 CPT/Diagnosis parity before it hits the clearinghouse. We look for "Waste Red-Flags" that AI-payers use to auto-delete high-value biologic lines.
We don't accept "No." We challenge every technical drug and diagnostic denial with clinical precision, leveraging our oncology-certified coders to file high-level appeals for your most complex cases.
Track your net collections, "Per-Visit Acuity Yield," and payer performance points with total transparency via our secure client portal.
To defend your oncology revenue in 2026, your infusion and treatment records must be bulletproof. We provide our oncology clients with a rigorous documentation checklist to ensure compliance:
In a technical audit for a 10-physician independent oncology group in the Southeast, MDRG identified a $282,000 annual revenue leakage in their drug-waste (JW) and biomarker testing billing. The group was failing to correctly document "Milligram-Level Waste" and was omitting the mandatory JZ modifier for zero-waste vials.
By implementing Revenue Cycle Management best practices, including real-time "Waste-Capture Training" for their clinical staff, MDRG was able to: * **Recover $188,000 in uncaptured drug waste and testing revenue** within the first 6 months. * **Reduce their "Waste-Mismatch" Denial Rate** by 72% using specialized technical narratives. * **Accelerate Cash Flow** by reducing their average days in A/R from 45 days to 23 days.
This oncology group now operates with "Audit-Armor" protection, knowing that every high-value patient hour is protected from automated payer clawbacks.
Rated 5.0 on Yelp. Read what practice owners say about working with us.
Every word below is a real review, posted publicly on Yelp.
“Our collections has increased tremendously.”
“I have worked with multiple billing companies, and honestly, MD Revenue has been the best experience. They are only a phone call away. When billing issues occur, they are hands-on and dive into the issues to solve them. Our collections has increased tremendously. 5 Star Company. Two thumbs up!!”
Fred A.
San Francisco, CA
“MD Revenue has been exceptional to work with.”
“Today I had a zoom meeting with them and MD Revenue has been exceptional to work with. Their team is extremely professional, clear in their communication, and consistent throughout the process. I highly recommend them to any business owner looking for reliable service.”
Rolando M.
Flushing, NY
“We always know where our claims stand.”
“MD Revenue Group provides good services for our chiropractic practice. Their team handles our billing efficiently and we always know where our claims stand. Communication has been clear and straightforward throughout. We are happy with the service and would recommend them to other practices.”
Dr. Manfred A.
Goodlife Chiro
In the high-intensity environment of 2026, your oncology practice deserves a revenue cycle that is as precise as your clinical care. Don't let your "Clinical Capital" be eroded by primitive billing and administrative friction.
Sent straight to your inbox. We respect medical practice privacy.
Oncology billing services range from 2.99% to 6.5% of net collections. We manage high-cost chemotherapy drug administration and clinical trial modifiers. Our certified oncology coders audit medication waste logs to ensure full margin recovery on biological therapies.
Onboarding an oncology practice requires mapping active chemotherapy regimens. We review drug authorization codes for all patients currently in treatment cycles, ensuring that new billing links are pre-authorized to prevent treatment gaps.
